NovaMed Pharmaceuticals

Shanghai, China Founded: 2005 • Age: 21 yrs Acquired By SciClone Pharmaceuticals
Therapeutics for oncology, cardiovascular, and CNS disorders are developed.
Request Access

About NovaMed Pharmaceuticals

NovaMed Pharmaceuticals is a company based in Shanghai (China) founded in 2005 was acquired by SciClone Pharmaceuticals in April 2011.. NovaMed Pharmaceuticals has raised $18.8 million across 2 funding rounds from investors including Atlas Venture, SciClone Pharmaceuticals and Eight Roads Ventures.

  • Headquarter Shanghai, China
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $18.8 M (USD)

    in 2 rounds

  • Latest Funding Round
    $13.8 M (USD), Series B

    Jan 22, 2008

  • Investors
  • Employee Count
    Employee Count
  • Acquired by
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of NovaMed Pharmaceuticals

NovaMed Pharmaceuticals has successfully raised a total of $18.8M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $13.8 million completed in January 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Series B — $13.8M
  • First Round

    (31 Jul 2007)

  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
Jan, 2008 Amount Series B - NovaMed Pharmaceuticals Valuation

investors

Jul, 2007 Amount Series A - NovaMed Pharmaceuticals Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in NovaMed Pharmaceuticals

NovaMed Pharmaceuticals has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Atlas Venture, SciClone Pharmaceuticals and Eight Roads Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Investor Description Founded Year Domain Location
Venture capital firm investing in life science and biotechnology sectors
Founded Year Domain Location
Venture capital investment and global platform support for startups.
Founded Year Domain Location
Specialty biopharma company that develops and commercializes specialist-oriented drugs
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by NovaMed Pharmaceuticals

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - NovaMed Pharmaceuticals

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Novamed Pharmaceuticals Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of NovaMed Pharmaceuticals

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Novamed Pharmaceuticals

Frequently Asked Questions about NovaMed Pharmaceuticals

When was NovaMed Pharmaceuticals founded?

NovaMed Pharmaceuticals was founded in 2005 and raised its 1st funding round 2 years after it was founded.

Where is NovaMed Pharmaceuticals located?

NovaMed Pharmaceuticals is headquartered in Shanghai, China.

Is NovaMed Pharmaceuticals a funded company?

NovaMed Pharmaceuticals is a funded company, having raised a total of $18.8M across 2 funding rounds to date. The company's 1st funding round was a Series A of $5M, raised on Jul 31, 2007.

What does NovaMed Pharmaceuticals do?

NovaMed Pharmaceuticals was founded in 2005 and is headquartered in Shanghai, China. The company operates in the pharmaceutical sector, where therapeutics are developed for oncology, cardiovascular disease, central nervous system disorders, urology, and infections. Key products include the broad-spectrum anti-convulsant Depakine, the anti-hypertension ACE inhibitor Tritace, the hypnotic anti-insomnia drug Stilnox, and the interventional cardiology product Aggrastat. Operations focus on research and development in these therapeutic areas.

Who are NovaMed Pharmaceuticals's investors?

NovaMed Pharmaceuticals has 3 investors. Key investors include Atlas Venture, SciClone Pharmaceuticals, and Eight Roads Ventures.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available